Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Blood|August 6, 2004
Induction of imatinib metabolism by hypericum perforatumPatrick F Smith, Julie M Bullock, Brent M Booker, et al.
British Journal of Clinical Pharmacology|December 29, 2020
Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2Kashyap Patel, Michael Dodds, Antonio Gonçalves, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjectsPeter N Morcos, Linda Chang, Mercidita Navarro, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2016
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus ProgressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2015
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Clinical Therapeutics|December 3, 2014
Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitorNavita L Mallalieu, Mohamad H Rahimy, Constance A Crowley, et al.
Therapeutic Drug Monitoring|January 19, 2006
Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantationJulie M Bullock, Patrick F Smith, Brent M Booker, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPatrick F Smith, Abayomi Ogundele, Alan Forrest, et al.
The Journal of Pharmacy and Pharmacology|October 15, 2013
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteersPeter N Morcos, Sebastian A Moreira, Mercidita T Navarro, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Blood|August 6, 2004
Induction of imatinib metabolism by hypericum perforatumPatrick F Smith, Julie M Bullock, Brent M Booker, et al.
British Journal of Clinical Pharmacology|December 29, 2020
Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2Kashyap Patel, Michael Dodds, Antonio Gonçalves, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjectsPeter N Morcos, Linda Chang, Mercidita Navarro, et al.
Antimicrobial Agents and Chemotherapy|February 28, 2016
Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus ProgressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2015
A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progressionMohamed A Kamal, Ronald Gieschke, Annabelle Lemenuel-Diot, et al.
Clinical Therapeutics|December 3, 2014
Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitorNavita L Mallalieu, Mohamad H Rahimy, Constance A Crowley, et al.
Therapeutic Drug Monitoring|January 19, 2006
Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantationJulie M Bullock, Patrick F Smith, Brent M Booker, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPatrick F Smith, Abayomi Ogundele, Alan Forrest, et al.
The Journal of Pharmacy and Pharmacology|October 15, 2013
Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteersPeter N Morcos, Sebastian A Moreira, Mercidita T Navarro, et al.
European Journal of Clinical Pharmacology|July 23, 2013
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktailPeter N Morcos, Linda Chang, Rohit Kulkarni, et al.
Pageof 7